cGMP

cGMP (current Good Manufacturing Practice) is the FDA regulatory framework codified at 21 CFR Parts 210 and 211 that sets minimum standards for pharmaceutical manufacturing facilities. cGMP covers facility design, equipment qualification, personnel training, manufacturing process validation, quality unit independence, batch records, in-process and finished product testing, complaint handling, and recall procedures. For 503B outsourcing facilities, FDA has issued cGMP guidance specifically tailored to the 503B context.

How cGMP works

cGMP imposes a continuous compliance obligation across every manufacturing operation. The facility design must support clean operations (HVAC, environmental controls, segregation). Equipment must be qualified and maintained. Personnel must be trained and competency-assessed. Each manufacturing process must be validated with documented evidence that it produces a product meeting predetermined specifications. The Quality Unit (Quality Assurance and Quality Control functions) must be independent of manufacturing operations and must have the authority to approve or reject batches.

FDA inspections at cGMP facilities apply the framework directly. Inspectional observations on a Form 483 commonly cite cGMP deficiencies; the 15-business-day response and any escalation to Warning Letter, consent decree, or injunction proceeds on the cGMP framework. Recall, import alert, and seizure also run on cGMP grounds.

When cGMP applies

cGMP applies to every facility that manufactures drugs for sale in the United States: traditional drug manufacturers (small molecule and biologics), 503B outsourcing facilities (under FDA's tailored cGMP guidance for 503B), API manufacturers, and contract manufacturing organizations (CMOs). 503A compounding pharmacies operate primarily under USP 797 and USP 795 standards through state board enforcement, with FDA cGMP jurisdiction attaching only when the 503A pharmacy steps outside the 503A framework (interstate scale, office-use compounding, bulks list violations).

The manufacturer's exposure under cGMP

FDA Form 483, Warning Letter, consent decree, injunction, recall, import alert, seizure, and criminal referral under the Park doctrine all run on cGMP grounds. Civil exposure under the False Claims Act surfaces where cGMP violations support adulteration or misbranding theories on government program claims. Criminal exposure under 21 USC 333 and the Park doctrine attaches to responsible corporate officers. The defense framework focuses on the cGMP compliance posture documentation, root cause analysis on cited deficiencies, corrective action and preventive action (CAPA) records, and the negotiation of consent decree terms where escalation has occurred.

Related terms

• 503A and 503B The compounding pathways where cGMP applies most directly to 503B facilities.
• Form 483 The FDA inspectional observations document that commonly cites cGMP deficiencies.
• FDA Warning Letter The enforcement document that often follows inadequate Form 483 response on cGMP findings.
• USP 797 and 800 The USP standards that operate alongside cGMP at compounding facilities.

See also

• Practice area
  FDA Warning Letter Response

  The full FDA enforcement defense framework spanning Form 483, Warning Letter, and cGMP escalation.

• Practice area
  503B Defense

  503B outsourcing facility defense framework specifically focused on cGMP compliance and FDA inspection response.